Solid microemulsion preconcentrate (NanOsorb) of artemether for effective treatment of malaria

International Journal of Pharmaceutics

Volumn 362, Issue 1-2, 2008, Pages 172-178

  Joshi, Medha ^a   Pathak, Sulabha ^b   Sharma, Shobhona ^b   Patravale, Vandana ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b TATA INSTITUTE OF FUNDAMENTAL RESEARCH   (India)

Author keywords

Antimalarial activity; Artemether; Malaria; Oral dosage form; Solid microemulsion preconcentrate

Indexed keywords

ADSORBENT; ARTEMETHER; CAPRYOL 90; CAPTEX; CAPTEX 200; CREMOPHOR; EXCIPIENT; GELUCIRE; LARITHER; LAUROGLYCOL; MIGLYOL; NANOSORB; OCTANOIN; OLEIC ACID; PEGLICOL 5 OLEATE; POLYSORBATE 20; POLYSORBATE 80; SOLUTOL HS 15; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; MALARIA; MALE; MICROEMULSION; MOUSE; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PLASMODIUM BERGHEI; PRIORITY JOURNAL; TOXICITY;

ANIMALS; ANTIMALARIALS; ARTEMISININS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRUG COMPOUNDING; EMULSIONS; LETHAL DOSE 50; MALARIA; MALE; MICE; OILS; PARTICLE SIZE; PLASMODIUM BERGHEI; SOLUBILITY; SURFACE-ACTIVE AGENTS; TOXICITY TESTS;

EID: 50549085646     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.06.012     Document Type: Article

References (24)

1. Abdul-Fattah A.M., and Bhargava H.N. Preparation and in vitro evaluation of solid dispersions of halofantrine. Int. J. Pharm. 235 (2002) 17-33
2. Barker S.A., Yap S.P., Yuen K.H., Mccoy C.P., Murphy J.R., and Craig D.Q. An investigation into the structure and bioavailability of alpha-tocopherol dispersions in Gelucire 44/14. J. Control Release 91 (2003) 477-488
3. Bhadra D., Yadav A.K., Bhadra S., and Jain N.K. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int. J. Pharm. 295 (2005) 221-233
4. Chimanuka B., Gabriels M., Detaevernier M.R., and Plaizier-Vercammen J.A. Preparation of beta-artemether liposomes, their HPLC-UV evaluation and relevance for clearing recrudescent parasitaemia in Plasmodium chabaudi malaria-infected mice. J. Pharm. Biomed. Anal. 28 (2002) 13-22
5. Date A.A., Joshi M.D., and Patravale V.B. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev. 59 (2007) 505-521
6. Date A.A., and Nagarsenker M.S. Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil. Int. J. Pharm. 329 (2007) 166-172
7. Fidock, D.A., Rosenthal, P.J., Croft, S.L., Brun, R., Nwaka, S., 2004. Antimalarial efficacy screening: in vitro and in vivo protocols, Supplemental file, antimalarial drug discovery: efficacy model for compound screening supplementary document available online http://www.mmv.org/FilesUpld/164.pdf (cross reference from Fidock et al., Nature Reviews Drug Discovery 3, 2004, 509-520)
8. Greenwood B., and Mutabingwa T. Malaria in 2002. Nature 415 (2002) 670-672
9. Ito Y., Kusawake T., Ishida M., Tawa R., Shibata N., and Takada K. Oral solid gentamicin preparation using emulsifier and adsorbent. J. Control Release 105 (2005) 23-31
10. Jeans C.W., and Heard C.M. A therapeutic dose of primaquine can be delivered across excised human skin from simple transdermal patches. Int. J. Pharm. 189 (1999) 1-6
11. Karbwang J., Na-Bangchang K., Congpuong K., Molunto P., and Thanavibul A. Pharmacokinetics and bioavailability of oral and intramuscular artemether. Eur. J. Clin. Pharmacol. 52 (1997) 307-310
12. Karunajeewa H.A., Reeder J., Lorry K., Dabod E., Hamzah J., Page-Sharp M., Chiswell G.M., Ilett K.F., and Davis T.M. Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New Guinea. Antimicrob. Agents Chemother. 50 (2006) 968-974
13. Krugliak M., Deharo E., Shalmiev G., Sauvain M., Moretti C., and Ginsburg H. Antimalarial effects of C18 fatty acids on Plasmodium falciparum in culture and on Plasmodium vinckei petteri and Plasmodium yoelii nigeriensis in vivo. Exp. Parasitol. 81 (1995) 97-105
14. Kumaratilake L.M., Robinson B.S., Ferrante A., and Poulos A. Antimalarial properties of n - 3 and n - 6 polyunsaturated fatty acids: in vitro effects on Plasmodium falciparum and in vivo effects on P. berghei. J. Clin. Invest. 89 (1992) 961-967
15. Lawrence M.J., and Rees G.D. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 45 (2000) 89-121
16. Lefèvre G., and Thomsen M.S. Clinical pharmacokinetics of artemether and lumefantrine (riamet). Clin. Drug Invest. 18 (1999) 467-480
17. OECD guidelines web site: http://www.oecd.org/dataoecd/63/7/32035886.pdf, accessed on 2nd February 2008.
18. Owais M., Varshney G.C., Choudhury A., Chandra S., and Gupta C.M. Chloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistant Plasmodium berghei infections in mice. Antimicrob. Agents Chemother. 39 (1995) 180-184
19. Peters W., Portus J.H., and Robinson B.L. The chemotherapy of rodent malaria. XXII. The value of drug-resistant strains of P. berghei in screening of blood schizonticidal activity. Ann. Trop. Med. Parasitol. 69 (1975) 155-171
20. Rodrigues J.M., Fessi H., Bories C., Puisieux F., and Devissaguet J.-P. Primaquine-loaded poly(lactide) nanoparticles: physicochemical study and acute tolerance in mice. Int. J. Pharm. 126 (1995) 253-260
21. Stensrud G., Sande S.A., Kristensen S., and Smistad G. Formulation and characterisation of primaquine loaded liposomes prepared by a pH gradient using experimental design. Int. J. Pharm. 198 (2000) 213-228
22. Ten Tije A.J., Verweij J., Loos W.J., and Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. 42 (2003) 665-685
23. WHO web site: http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf, accessed on 2nd February 2008.
24. Yuksel N., Karatas A., Ozkan Y., Savaser A., Ozkan S.A., and Baykara T. Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 56 (2003) 453-459